ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 733,50
0,31%
Dow Jones
43 487,83
0,78%
DAX
20 990,31
0,44%
Brent Oil
79,465
-0,93%
Bitcoin
103 216,66
0,10%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Supernus Pharmaceuticals Inc (SUPN)

  7. Supernus Pharmaceuticals Inc (SUPN) Actualités

SUPN

Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SUPN
DateHeureSourceTitreSymboleSociété
30/12/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
20/12/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
16/12/202422h30GlobeNewswire Inc.Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in CanadaNASDAQ:SUPNSupernus Pharmaceuticals Inc
03/12/202422h31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
26/11/202423h00GlobeNewswire Inc.Supernus to Participate in the 36th Annual Piper Sandler Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
14/11/202423h14Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SUPNSupernus Pharmaceuticals Inc
13/11/202422h30GlobeNewswire Inc.Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
04/11/202422h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SUPNSupernus Pharmaceuticals Inc
04/11/202422h05GlobeNewswire Inc.Supernus Announces Third Quarter 2024 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
31/10/202421h10GlobeNewswire Inc.Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024NASDAQ:SUPNSupernus Pharmaceuticals Inc
21/10/202422h25GlobeNewswire Inc.Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
18/10/202412h09IH Market NewsiPhone 16 Sales in China Up 20%; Sobr Safe Jumps 108% Pre-Market; Netflix and Intuitive Surgical Beat EstimatesNASDAQ:SUPNSupernus Pharmaceuticals Inc
17/10/202422h05GlobeNewswire Inc.Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive DisorderNASDAQ:SUPNSupernus Pharmaceuticals Inc
10/10/202423h12GlobeNewswire Inc.Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive DisorderNASDAQ:SUPNSupernus Pharmaceuticals Inc
24/09/202413h30GlobeNewswire Inc.Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and QelbreeNASDAQ:SUPNSupernus Pharmaceuticals Inc
19/09/202422h30GlobeNewswire Inc.Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry SummitNASDAQ:SUPNSupernus Pharmaceuticals Inc
28/08/202422h15GlobeNewswire Inc.Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
19/08/202413h00GlobeNewswire Inc.Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDANASDAQ:SUPNSupernus Pharmaceuticals Inc
06/08/202422h06GlobeNewswire Inc.Supernus Announces Second Quarter 2024 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
01/08/202422h30GlobeNewswire Inc.Supernus Resubmits NDA for SPN-830 Apomorphine Infusion DeviceNASDAQ:SUPNSupernus Pharmaceuticals Inc
23/07/202422h13GlobeNewswire Inc.Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024NASDAQ:SUPNSupernus Pharmaceuticals Inc
17/06/202423h15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SUPNSupernus Pharmaceuticals Inc
30/05/202422h25GlobeNewswire Inc.Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
23/05/202422h05GlobeNewswire Inc.Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in EpilepsyNASDAQ:SUPNSupernus Pharmaceuticals Inc
09/05/202422h05GlobeNewswire Inc.Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant SeizuresNASDAQ:SUPNSupernus Pharmaceuticals Inc
08/05/202422h05GlobeNewswire Inc.Supernus Announces First Quarter 2024 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
07/05/202416h00PR Newswire (US)M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin AmericaNASDAQ:SUPNSupernus Pharmaceuticals Inc
01/05/202414h00GlobeNewswire Inc.Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree StoryNASDAQ:SUPNSupernus Pharmaceuticals Inc
24/04/202422h05GlobeNewswire Inc.Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024NASDAQ:SUPNSupernus Pharmaceuticals Inc
08/04/202414h00GlobeNewswire Inc.Supernus Provides Regulatory Update for SPN-830NASDAQ:SUPNSupernus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SUPN

Dernières Valeurs Consultées

BIT
NSCIT0536515
Italian Republic
AQSE
FGQI.GB
FIL Fund Management Irel...
AQSE
UKCO.GB
State Street Global Advi...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés